Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Colorcon
Medtronic
Merck
Johnson and Johnson
Dow
AstraZeneca

Last Updated: February 7, 2023

CLINICAL TRIALS PROFILE FOR TOTECT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Totect

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00016276 ↗ Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Terminated National Cancer Institute (NCI) Phase 3 2001-05-01 Randomized phase III trial to compare the effectiveness of combination chemotherapy, surgery, and radiation therapy with or without dexrazoxane and trastuzumab in treating women who have stage IIIA, stage IIIB or stage IV breast cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dexrazoxane, may protect normal cells from the side effects of chemotherapy. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known if chemotherapy combined with surgery and radiation therapy is more effective with or without dexrazoxane and trastuzumab in treating breast cancer
NCT00039481 ↗ Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors Completed National Cancer Institute (NCI) Phase 1 2002-11-01 Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Oblimersen may increase the effectiveness of doxorubicin and cyclophosphamide by making the tumor cells more sensitive to the drug. Chemoprotective drugs such as dexrazoxane may protect normal cells from the side effects of chemotherapy
NCT00084838 ↗ Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT Completed National Cancer Institute (NCI) Phase 2 2003-02-01 RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Totect

Condition Name

Condition Name for Totect
Intervention Trials
Unspecified Childhood Solid Tumor, Protocol Specific 3
Recurrent Childhood Anaplastic Large Cell Lymphoma 2
Cardiac Toxicity 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Totect
Intervention Trials
Leukemia 4
Precursor Cell Lymphoblastic Leukemia-Lymphoma 3
Leukemia, Lymphoid 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Totect

Trials by Country

Trials by Country for Totect
Location Trials
United States 216
Canada 23
Australia 5
Puerto Rico 4
New Zealand 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Totect
Location Trials
Texas 8
California 8
Pennsylvania 7
Ohio 7
Minnesota 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Totect

Clinical Trial Phase

Clinical Trial Phase for Totect
Clinical Trial Phase Trials
Phase 3 4
Phase 2 2
Phase 1/Phase 2 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Totect
Clinical Trial Phase Trials
Completed 4
Recruiting 4
Terminated 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Totect

Sponsor Name

Sponsor Name for Totect
Sponsor Trials
National Cancer Institute (NCI) 10
Children's Oncology Group 5
EsPhALL network I-BFM Study Group 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Totect
Sponsor Trials
NIH 10
Other 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Dow
AstraZeneca
McKinsey
McKesson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.